JP2013507352A5 - - Google Patents

Download PDF

Info

Publication number
JP2013507352A5
JP2013507352A5 JP2012532683A JP2012532683A JP2013507352A5 JP 2013507352 A5 JP2013507352 A5 JP 2013507352A5 JP 2012532683 A JP2012532683 A JP 2012532683A JP 2012532683 A JP2012532683 A JP 2012532683A JP 2013507352 A5 JP2013507352 A5 JP 2013507352A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
pharmaceutically acceptable
acceptable salt
composition according
propargyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012532683A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013507352A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2010/002852 external-priority patent/WO2011042812A1/en
Publication of JP2013507352A publication Critical patent/JP2013507352A/ja
Publication of JP2013507352A5 publication Critical patent/JP2013507352A5/ja
Pending legal-status Critical Current

Links

JP2012532683A 2009-10-09 2010-10-08 進行性核上性麻痺の治療のためのラサギリンの使用 Pending JP2013507352A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27867709P 2009-10-09 2009-10-09
US61/278,677 2009-10-09
PCT/IB2010/002852 WO2011042812A1 (en) 2009-10-09 2010-10-08 Use of rasagiline for the treatment of progressive supranuclear palsy

Publications (2)

Publication Number Publication Date
JP2013507352A JP2013507352A (ja) 2013-03-04
JP2013507352A5 true JP2013507352A5 (enExample) 2013-11-28

Family

ID=43533485

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012532683A Pending JP2013507352A (ja) 2009-10-09 2010-10-08 進行性核上性麻痺の治療のためのラサギリンの使用

Country Status (7)

Country Link
US (1) US20110130466A1 (enExample)
EP (1) EP2485722A1 (enExample)
JP (1) JP2013507352A (enExample)
AU (1) AU2010304755A1 (enExample)
CA (1) CA2777185A1 (enExample)
IL (1) IL218948A0 (enExample)
WO (1) WO2011042812A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090111892A1 (en) * 2004-11-24 2009-04-30 Shulamit Patashnik Rasagiline Orally Disintegrating Compositions
JP5701485B2 (ja) * 2006-02-21 2015-04-15 テバ ファーマシューティカル インダストリーズ リミティド 多系統萎縮症の治療のためのラサギリンの使用
CA2646250A1 (en) * 2006-04-03 2007-10-18 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of restless legs syndrome
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
ZA200903903B (en) * 2006-12-14 2010-08-25 Teva Pharma Crystalline solid rasagiline base
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
AU2008296908B2 (en) * 2007-09-05 2014-01-09 Teva Pharmaceutical Industries, Ltd. Method of treating glaucoma using rasagiline
US20090181086A1 (en) * 2008-01-11 2009-07-16 Muhammad Safadi Rasagiline formulations, their preparation and use
WO2009151594A1 (en) * 2008-06-10 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
JP2011522892A (ja) * 2008-06-13 2011-08-04 テバ ファーマシューティカル インダストリーズ リミティド パーキンソン病緩和のためのラサギリン
AU2009260733B2 (en) * 2008-06-19 2015-01-29 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
MX2010013875A (es) * 2008-06-19 2011-01-20 Teva Pharma Proceso para preparar y secar base de rasagilina solida.
US20100189790A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
SI2451771T1 (sl) 2009-07-09 2014-10-30 Ratiopharm Gmbh Soli rasagilina in njihovi farmacevtski pripravki
AU2010341499A1 (en) * 2009-12-22 2012-08-09 Teva Pharmaceutical Industries Ltd. 3-keto-N-propargyl-1-aminoindan
CA2806740A1 (en) 2010-07-27 2012-02-02 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
AU2011282716A1 (en) 2010-07-27 2013-03-14 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
JP2014534197A (ja) 2011-10-10 2014-12-18 テバ ファーマシューティカル インダストリーズ リミティド R(+)−n−メチル−プロパルギルアミノインダン
WO2013055687A2 (en) 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. R(+)-n-formyl-propargyl-aminoindan
US9308182B2 (en) 2012-08-17 2016-04-12 Teva Pharmaceutical Industries, Ltd. Parenteral formulations of rasagiline

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090111892A1 (en) * 2004-11-24 2009-04-30 Shulamit Patashnik Rasagiline Orally Disintegrating Compositions
MX2008012479A (es) * 2006-03-29 2009-08-13 Velacor Therapeutics Pty Ltd Tratamiento de enfermedades neurodegenerativas.
EP1892233A1 (de) * 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
WO2009054544A1 (en) * 2007-10-26 2009-04-30 Eisai R & D Management Co., Ltd. Ampa receptor antagonists for parkinson's disease and movement disorders
MX2010013875A (es) * 2008-06-19 2011-01-20 Teva Pharma Proceso para preparar y secar base de rasagilina solida.
AU2009260733B2 (en) * 2008-06-19 2015-01-29 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
DE102008064061A1 (de) * 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US20100189790A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
AU2011282716A1 (en) * 2010-07-27 2013-03-14 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
CA2806740A1 (en) * 2010-07-27 2012-02-02 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
US20120101168A1 (en) * 2010-10-26 2012-04-26 Eliezer Bahar Deuterium enriched rasagiline
CN103857389A (zh) * 2011-10-10 2014-06-11 泰华制药工业有限公司 雷沙吉兰柠檬酰胺
WO2013055687A2 (en) * 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. R(+)-n-formyl-propargyl-aminoindan
JP2014534197A (ja) * 2011-10-10 2014-12-18 テバ ファーマシューティカル インダストリーズ リミティド R(+)−n−メチル−プロパルギルアミノインダン

Similar Documents

Publication Publication Date Title
JP2013507352A5 (enExample)
JP2013533287A5 (enExample)
PH12014502447A1 (en) Use of high dose laquinimod for treating multiple sclerosis
NZ589445A (en) Rasagiline for parkinson's disease modification
JP2011225596A5 (enExample)
NZ611628A (en) Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
JP2005506370A5 (enExample)
JP2016163571A5 (enExample)
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
FI3504187T3 (fi) Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
JP2021523895A5 (enExample)
JP2011516417A5 (enExample)
JP2014526503A5 (enExample)
JP2014521735A5 (enExample)
RU2013108258A (ru) Применение разагилина для лечения обонятельной дисфункции
JP2011528333A5 (enExample)
JP2019535760A5 (ja) ガボキサドールを用いた注意欠陥多動性障害(adhd)の治療方法
JP2012517478A5 (enExample)
PE20081106A1 (es) Comprimidos pediatricos de capecitabina
JP2014508758A5 (enExample)
JP2021073257A5 (enExample)
JP2012531402A5 (enExample)
MX350195B (es) Analogos de cistamina para el tratamiento de la enfermedad de parkinson.
JP2014524478A5 (enExample)
JP2008534503A5 (enExample)